7:37 AM ET
8-K
Stock Buyback
Alnylam Pharmaceuticals Announces $1B Stock Buyback
Alnylam Pharmaceuticals announced that its Board of Directors authorized a new $1.0 billion share repurchase program. The company expects to repurchase approximately $500 million of its common stock by the end of 2026, with the remaining balance planned for 2027. Additionally, the company disclosed that Tolga Tanguler will depart from his role as Executive Vice President and Chief Commercialization Officer in December 2026.
- Value
- $1B